8-K: Personalis Reports 18% Revenue Increase in Q4 2023, Forges Key Partnerships

Personalis, Inc. announced an 18% increase in fourth-quarter revenue and key strategic partnerships, while also providing its financial outlook for 2024.

Summary

• Personalis reported a total revenue of $19.7 million for the fourth quarter of 2023, an 18% increase compared to $16.7 million in the same period of 2022.
• Revenue from pharma tests, enterprise, and other customers reached $18.7 million in Q4 2023, up from $15.8 million in Q4 2022, which includes $7.1 million from Natera compared to $8.2 million in the prior year.
• The company's revenue from population sequencing for the U.S. Department of Veterans Affairs Million Veterans Program (VA MVP) was $1.0 million in Q4 2023, compared to $0.9 million in Q4 2022.
• Personalis experienced a net loss of $26.6 million in Q4 2023, or $0.54 per share, compared to a net loss of $31.1 million, or $0.67 per share, in Q4 2022.
• For the full year 2023, Personalis reported total revenue of $73.5 million, a 13% increase from $65.0 million in 2022.
• Full-year revenue from pharma tests, enterprise, and other customers was $64.1 million in 2023, compared to $56.6 million in 2022, including $31.7 million from Natera compared to $26.6 million in the prior year.
• The company's full-year revenue from the VA MVP was $9.4 million in 2023, compared to $8.4 million in 2022.
• Personalis reported a net loss of $108.3 million for the full year 2023, or $2.25 per share, compared to a net loss of $113.3 million, or $2.48 per share, in 2022.
• Cash usage for the full year 2023 was $53.5 million, a significant decrease from $119.4 million in 2022.
• The company expects total revenue to be between $18.0 and $19.0 million for the first quarter of 2024 and between $73.0 and $75.0 million for the full year 2024.
• Personalis anticipates a net loss of approximately $80.0 million for 2024, down from $108.3 million in 2023, and cash usage of approximately $62.0 million for 2024.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong revenue growth and strategic partnerships, but the continued net losses and risks associated with the business model temper the overall sentiment. The reduction in cash usage is a positive sign.

Positives

• The company experienced an 18% increase in Q4 revenue and a 13% increase in full year revenue.
• Personalis secured Medicare coverage for its NeXT Dx test, which will significantly expand its market reach.
• Strategic partnerships with Tempus, Myriad, and ClearNote are expected to drive commercial growth and expand service offerings.
• The company has reduced its cash usage from $119.4 million in 2022 to $53.5 million in 2023.
• The company is projecting a reduced net loss of approximately $80 million for 2024, down from $108.3 million in 2023.

Negatives

• Personalis reported a net loss of $26.6 million in Q4 2023 and $108.3 million for the full year 2023.
• The company's other expenses increased to $4.1 million in Q4 2023 and for the full year 2023, including a $4.0 million non-cash expense related to warrants issued to Tempus.
• Revenue from Natera decreased in Q4 2023 compared to Q4 2022, from $8.2 million to $7.1 million.

Risks

• The company's future performance is subject to the timing and pace of new orders from customers, including Natera and the VA MVP.
• The timing of tissue, blood, and other specimen sample receipts from customers can materially impact revenue quarter-over-quarter and year-over-year.
• There are risks associated with demonstrating the attributes, advantages, or clinical validity of the NeXT Personal Dx test.
• The company's ability to obtain reimbursement for its tests is not guaranteed.
• The success of the collaboration and co-commercialization agreement with Tempus is subject to various factors, including Tempus' sales and marketing efforts.
• The adoption and use of the NeXT Personal Dx test by oncologists is not guaranteed.

Future Outlook

Personalis expects total revenue to be in the range of $18.0 to $19.0 million for the first quarter of 2024 and $73.0 to $75.0 million for the full year 2024. The company anticipates a net loss of approximately $80.0 million for 2024 and cash usage of approximately $62.0 million.

Management Comments

• Chris Hall, Chief Executive Officer, stated that the company ended 2023 with strong execution, delivering on commitments including launching NeXT Personal Dx and establishing commercial partnerships.
• Mr. Hall also mentioned that the company's efforts in 2024 are focused on executing its Win-in-MRD strategy for NeXT Personal.

Industry Context

This announcement reflects the growing importance of precision oncology and minimal residual disease (MRD) testing in cancer management. The partnerships with Tempus, Myriad, and ClearNote indicate a trend towards collaboration and expansion of service offerings in the genomics space. The Medicare coverage determination is a significant milestone for Personalis, aligning with the industry's push for broader access to advanced genomic testing.

Comparison to Industry Standards

• Personalis' revenue growth of 18% in Q4 2023 is a positive sign, but it is important to compare this to other companies in the genomics and precision oncology space, such as Exact Sciences (EXAS) or Guardant Health (GH), which have also been experiencing growth in their respective markets.
• The strategic partnerships with Tempus, Myriad, and ClearNote are similar to moves made by other companies in the industry to expand their reach and offerings, such as Illumina's (ILMN) collaborations with various pharmaceutical companies.
• The reduction in cash usage from $119.4 million to $53.5 million is a significant improvement and is a key metric that investors will be watching closely, as many companies in this sector are still in the growth phase and are not yet profitable.
• The projected net loss of $80 million for 2024 is still substantial, and it will be important to see how Personalis' performance compares to other companies in the sector that are also working towards profitability.

Stakeholder Impact

• Shareholders will be impacted by the financial results, strategic partnerships, and future outlook.
• Employees may be impacted by the company's restructuring and headcount reductions.
• Customers will benefit from the expanded access to Personalis' genomic testing services.
• Partners will be impacted by the success of the collaborations and co-commercialization agreements.
• Creditors will be impacted by the company's financial performance and cash usage.

Next Steps

• Personalis will focus on executing its Win-in-MRD strategy for NeXT Personal in 2024.
• The company will continue to generate clinical evidence to support Medicare coverage for its tests.
• Personalis will leverage its early success with biopharma customers to accelerate adoption of its products.
• The company will utilize a partner-centric strategy to accelerate commercialization in a capital-efficient manner.

Key Dates

Keywords

genomics, oncology, precision medicine, MRD, NeXT Personal Dx, Medicare, Tempus, Myriad, ClearNote, Natera, VA MVP, biomarker, cancer